- Home
- RRR vs ACLX Comparison
RRR vs ACLX Comparison
Compare RRR & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRR
- ACLX
- Stock Information
- Founded
- RRR 1976
- ACLX 2015
- Country
- RRR United States
- ACLX United States
- Employees
- RRR N/A
- ACLX N/A
- Industry
- RRR Hotels/Resorts
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- RRR Consumer Discretionary
- ACLX Health Care
- Exchange
- RRR Nasdaq
- ACLX Nasdaq
- Market Cap
- RRR 3.7B
- ACLX 4.1B
- IPO Year
- RRR 2016
- ACLX 2022
- Fundamental
- Price
- RRR $60.63
- ACLX $77.28
- Analyst Decision
- RRR Buy
- ACLX Strong Buy
- Analyst Count
- RRR 12
- ACLX 13
- Target Price
- RRR $60.25
- ACLX $114.75
- AVG Volume (30 Days)
- RRR 613.0K
- ACLX 507.4K
- Earning Date
- RRR 11-06-2025
- ACLX 11-06-2025
- Dividend Yield
- RRR 3.30%
- ACLX N/A
- EPS Growth
- RRR 3.75
- ACLX N/A
- EPS
- RRR 2.94
- ACLX N/A
- Revenue
- RRR $1,987,845,000.00
- ACLX $56,979,000.00
- Revenue This Year
- RRR $4.18
- ACLX N/A
- Revenue Next Year
- RRR $3.51
- ACLX $174.18
- P/E Ratio
- RRR $20.65
- ACLX N/A
- Revenue Growth
- RRR 7.47
- ACLX N/A
- 52 Week Low
- RRR $35.09
- ACLX $47.86
- 52 Week High
- RRR $63.60
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- RRR 50.91
- ACLX 62.98
- Support Level
- RRR $58.84
- ACLX $73.16
- Resistance Level
- RRR $61.29
- ACLX $79.49
- Average True Range (ATR)
- RRR 1.33
- ACLX 2.72
- MACD
- RRR -0.39
- ACLX 0.53
- Stochastic Oscillator
- RRR 40.50
- ACLX 82.31
About RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.